Comparative Pharmacology
Head-to-head clinical analysis: CARVEDILOL versus MARCAINE HYDROCHLORIDE W EPINEPHRINE PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARVEDILOL versus MARCAINE HYDROCHLORIDE W EPINEPHRINE PRESERVATIVE FREE.
CARVEDILOL vs MARCAINE HYDROCHLORIDE W/ EPINEPHRINE PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carvedilol is a nonselective beta-adrenergic receptor antagonist (beta-1, beta-2) and alpha-1 adrenergic receptor antagonist. It causes vasodilation and reduces heart rate, myocardial contractility, and blood pressure. It also has antioxidant and anti-proliferative effects.
Bupivacaine blocks sodium ion channels on the neuronal membrane, inhibiting depolarization and conduction of nerve impulses. Epinephrine causes local vasoconstriction, delaying absorption and prolonging anesthetic effect.
Heart failure: Initial 3.125 mg orally twice daily, titrate every 2 weeks to 6.25 mg, 12.5 mg, then 25 mg twice daily as tolerated. Target dose: 25 mg twice daily (≤85 kg) or 50 mg twice daily (>85 kg). Hypertension: Initial 6.25 mg orally twice daily, titrate every 1-2 weeks to 12.5 mg, then 25 mg twice daily. Maximum: 50 mg twice daily.
Local infiltration: up to 30 mL of 0.25% (75 mg) or 0.5% (150 mg) solution. Epidural (lumbar): 10-20 mL of 0.5% (50-100 mg) with 1:200,000 epinephrine, repeated every 1.5-3 hours as needed. Maximum single dose: 225 mg (with epinephrine 1:200,000).
None Documented
None Documented
Clinical Note
moderateCarvedilol + Digitoxin
"Carvedilol may increase the bradycardic activities of Digitoxin."
Clinical Note
moderateCarvedilol + Deslanoside
"Carvedilol may increase the bradycardic activities of Deslanoside."
Clinical Note
moderateCarvedilol + Acetyldigitoxin
"Carvedilol may increase the bradycardic activities of Acetyldigitoxin."
Clinical Note
moderateCarvedilol + Ouabain
"Carvedilol may increase the bradycardic activities of Ouabain."
Terminal elimination half-life is 7-10 hours. Steady-state concentrations are achieved within 2-3 days. Clinical context: Twice-daily dosing provides consistent beta-blockade and vasodilation.
Terminal half-life of bupivacaine is 2.7–4.2 hours in adults; prolonged to 8–12 hours in neonates and patients with hepatic impairment.
Primarily hepatic metabolism, with less than 2% excreted unchanged in urine. Metabolites are excreted in bile and feces; renal clearance of metabolites accounts for ~16% of total clearance. Fecal excretion of metabolites is ~60%.
Primarily hepatic metabolism via CYP3A4 and amide hydrolysis; <5% excreted unchanged in urine. Biliary excretion accounts for <2% of total elimination.
Category C
Category A/B
Alpha/Beta-Blocker
Alpha/Beta Agonist